#SKG1108
LightNews LightNews
newsen.bsky.social
Skyline Therapeutics Unveils Innovative Gene Therapy for Vision Loss at ASGCT 2025#None#New_Orleans#retinitis_pigmentosa#Skyline_Therapeutics#SKG1108
Skyline Therapeutics Unveils Innovative Gene Therapy for Vision Loss at ASGCT 2025
Skyline Therapeutics showcases their groundbreaking gene therapy, SKG1108, aimed at restoring vision in Retinitis Pigmentosa patients. Join the advancements.
third-news.com
May 10, 2025 at 4:12 PM
l2plabs.bsky.social
Skyline Therapeutics Presents Late-Breaking Abstract on SKG1108, a Novel Optogenetic Gene Therapy for Retinitis Pigmentosa, at ASGCT 2025
SHANGHAI, May 10, 2025 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven clinical-stage gene therapy company focused on developing unique and novel solutions for rare and severe diseases, today announced a late-breaking abstract presentation on SKG1108, its investigational...
dlvr.it
May 10, 2025 at 4:01 PM
drtimos.bsky.social
Thoughts on this? >> Skyline Therapeutics Presents Late-Breaking Abstract on
SKG1108, a Novel Optogenetic Gene Therapy for Retinitis Pigmentosa,
at ASGCT 2025 - The… >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #pharma #healthcare #biotech
Skyline Therapeutics Presents Late-Breaking Abstract on SKG1108, a Novel Optogenetic Gene Therapy for Retinitis Pigmentosa, at ASGCT 2025 - The Manila Times
Skyline Therapeutics Presents Late-Breaking Abstract on SKG1108, a Novel Optogenetic Gene Therapy for Retinitis Pigmentosa, at ASGCT 2025  The Manila Times
dlvr.it
May 10, 2025 at 10:00 PM
drtimos.bsky.social
Thoughts on this? >> Skyline Therapeutics Presents Late-Breaking Abstract on
SKG1108, a Novel Optogenetic Gene Therapy for Retinitis Pigmentosa,
at ASGCT 2025 >> Comment below! #industry40 #mhealth #healthtech #IoT #AI
Skyline Therapeutics Presents Late-Breaking Abstract on SKG1108, a Novel Optogenetic Gene Therapy for Retinitis Pigmentosa, at ASGCT 2025
SHANGHAI, May 10, 2025 /PRNewswire/ — Skyline Therapeutics, an innovation-driven clinical-stage gene therapy company focused on developing unique and novel solutions for rare and severe diseases, today announced a late-breaking abstract presentation on SKG1108, its investigational optogenetic gene therapy for Retinitis Pigmentosa (RP), at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting (May 13–17, …
dlvr.it
May 10, 2025 at 5:28 PM